PatientsVille.com Logo

MUSCULAR WEAKNESS and Ativan

PatientsVille

MUSCULAR WEAKNESS Symptoms and Causes

Myasthenia gravis is a disease that causes weakness in your voluntary muscles. These are the muscles that you control. For example, you may have weakness in the muscles for eye movement, facial expressions, and swallowing. You can also have weakness in other muscles. This weakness gets worse with activity, and better with rest.

Myasthenia gravis is an autoimmune disease. Your body's immune system makes antibodies that block or change some of the nerve signals to your muscles. This makes your muscles weaker.

Other conditions can cause muscle weakness, so myasthenia gravis can be hard to diagnose. Tests used to make a diagnosis include blood, nerve, muscle, and imaging tests.

With treatment, the muscle weakness often gets much better. Medicines can help improve nerve-to-muscle messages and make muscles stronger. Other drugs keep your body from making so many abnormal antibodies. These medicines can have major side effects, so they should be used carefully. There are also treatments which filter abnormal antibodies from the blood or add healthy antibodies from donated blood. Sometimes, surgery to take out the thymus gland helps.

Some people with myasthenia gravis go into remission. This means that they do not have symptoms. The remission is usually temporary, but sometimes it can be permanent.

NIH: National Institute of Neurological Disorders and Stroke

Check out the latest treatments for MUSCULAR WEAKNESS

MUSCULAR WEAKNESS treatment research studies

Ativan clinical trials, surveys and public health registries


Find Drug Side Effect reports



Ativan Side Effects

Anxiety (68)
Pain (51)
Insomnia (44)
Depression (42)
Confusional State (41)
Dyspnoea (36)
Nausea (36)
Headache (36)
Somnolence (34)
Fatigue (34)
Asthenia (32)
Feeling Abnormal (30)
Amnesia (30)
Dizziness (29)
Agitation (28)
Diarrhoea (27)
Hallucination (25)
Loss Of Consciousness (23)
Death (23)
Convulsion (22)
Aggression (22)
Fall (21)
Vomiting (21)
Overdose (21)
Tremor (20)
Pneumonia (20)
Condition Aggravated (20)
Hypotension (20)
Pulmonary Embolism (18)
Depressed Level Of Consciousness (17)
Rash (17)
Dehydration (17)
Coma (17)
Decreased Appetite (16)
Abdominal Pain (16)
Malaise (16)
Mental Status Changes (16)
Constipation (15)
Palpitations (14)
Disorientation (14)
Injury (14)
Pyrexia (13)
Nervousness (13)
Tachycardia (13)
Vision Blurred (13)
Emotional Distress (12)
Deep Vein Thrombosis (12)
Pruritus (12)
Urinary Tract Infection (12)
Pain In Extremity (12)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

Does valium cause afib?

I hade bacterial prostatit and i used too many antibiotik but not help but when i used alprazolam or ativan sudenly i became okai but problem is i dident find ativan in ukraine and my sister always send to me ativan frome canada some body plea

I took this for 3 weeks and by the end of my treatment I wanted to shoot everyone in my home, myself included.

I was having bad dreams and anxiety attacks (My Mom was murdered in 2005). I started drinking to calm my nerves, but decided to quit alcohol. I was told by a nurse that quiting 'Cold Turkey' could be dangerous, so I went to see th

My email is skynet.ukr@ukr.net

My mother in law has been taking ativan 4 times a day , every since then she has fallen and broke her nose twice in less than four mths apart,effected her eye sight,confussion,disorented,cant remember anything are anybody. They need to take this crap

What I have been exsperiencing is when I want to go to sleep I start having vivid confusing images that don't make sense. I will be thinking about my day then a thought like eating ice cream and cake will pop in my mind and I never ate ice

<b><span style='font-weight: normal;'><b>After 6 weeks of oral lamisil I experienced</b>eczema, muscle weakness, asthma, bloody bowels, lower abdominal pain, dizziness, extreme f

<strong></strong><span style='color: #ffa500;'>I am experiencing severe muscular <span style='color: #0000ff;'>pain/muscle tighteningin the diaphragm and sometimes &

<strong>I am on Cipralex now for about 2-3 months -10mg in the morning for depression, and now am experiencing chronic muscle weakness, chronic pain in both wrists and left hip, chronic fatigue, nausea, constant dizziness, tremors/shaky, restle

2 patients given thiocolchicoside reported of muscular stiffness,uneasiness,insomnia,breathlessness and feeling of restlessness, 2 out of 5 patients have reported such experiences after consuming thiocolchicoside.i strongly recommend to withdraw this

Afeccion cardiaca,pues a pesar de hacer ejercicio se me bloquearon las arterias,por mucho colesterol y tuvieron que hacerme un cateterismo, tengo once aos de que me detectaron la enfermedad. He perdido masa muscular pero nado ycamino dos o tres ve

After 18 months, great fatigue and muscular pain. Is this due to Intragam? consultant thinks I'm being fussy

After a 1 week course of Trimethoprim 200mg. I developed mild thrush on day3, muscle weakness for 1 day on the day after completion of the course and, 3 days after completion generalised urticaria. Not sure if this is delayed sensitivity but I assu

After finnishing the dose for Artequin I started feeling, body twitching, weakness,dizzness, body cramps, headache, neck pain, sore joints and now am at my sixth day after the dose and still experiencing the side effects..

After my first injection on Friday three weeks ago I experienced numbness and weakness Sunday night after injection along with a fever and night sweats. Went back to doctor on Tuesday and had an ultrasound to see if blockages or blood clots everythin

After takin tablets, i am feelimg somewhat uneasyness, feeling weakness, food intake is reduced

MUSCULAR WEAKNESS Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Unknown  Acute Effect of Lorazepam on Brain Activity Measured by Magnetoencephalograpy (MEG) and Electroencephalography (EEG)
Condition: Healthy Subjects
Interventions: Drug: Lorazepam;   Drug: Placebo
Outcome Measures: Correlated Brain Activity using MEG and SNI analysis;   Correlated Brain Activity using MEG and standard analyses
2 Unknown  Effect of Additive Lorazepam on Patient Satisfaction as a Premedication in Diagnostic Flexible Bronchoscopy
Condition: Patient Satisfaction for Bronchoscopy
Interventions: Drug: Lorazepam;   Drug: Control
Outcome Measures: patient satisfaction;   relationship between patient satisfaction and sleep quality, anxiety level
3 Unknown  IM Olanzapine Versus IM Haloperidol Plus Lorazepam for Acute Agitation in Schizophrenia
Conditions: Schizophrenia;   Schizoaffective Disorder;   Agitation
Interventions: Drug: IM olanzapine;   Drug: haloperidol plus lorazepam IM
Outcome Measures: Positive and Negative Symptom Scale Excited Component (PANSS-EC);   Agitation-Calmness Evaluation Scale (ACES)
4 Recruiting Haloperidol and Lorazepam for Delirium in Patients With Advanced Cancer
Condition: Advanced Cancers
Interventions: Drug: Lorazepam;   Drug: Placebo;   Drug: Haloperidol decanoate;   Behavioral: Questionnaires
Outcome Measure: Control of Delirium Symptoms
5 Recruiting The Cognitive Effects of Lorazepam in Healthy Older Individuals With TOMM40 Variable-length Polymorphisms
Condition: Alzheimer's Disease (AD)
Intervention: Drug: lorazepam
Outcome Measures: AVLT Long term memory score;   Groton Maze Learning Test (GMLT) score
6 Recruiting Comparison Between Lorazepam, Clonazepam and Clonazepam + Fosphenytoin for the Treatment of Out-of-hospital Generalized Status Epilepticus
Conditions: Status Epilepticus;   Epilepsy
Interventions: Drug: Clonazepam;   Drug: Fosphenytoin;   Drug: Placebo;   Drug: Lorazepam
Outcome Measures: Percentage of patient with a cessation of seizures and absence of recurrence;   Duration between the first cessation and the recurrence of seizures;   Percentage of patients having had a second injection of benzodiazepine;   Percentage of patients having had an injection of the second line treatment;   Percentage of patients having a general anesthesia for refractory status epilepticus;   Percentage of patients having had a side effect;   Percentage of patients having been mechanically ventilated;   Glasgow Coma Scale;   Mortality;   Length of stay in Intensive Care Unit;   Length of stay in hospital
7 Not yet recruiting Clobazam Use in Epilepsia Partialis Continua - Pilot Study
Conditions: Epilepsia Partialis Continua;   Kojewnikov's Epilepsy;   Epilepsy
Interventions: Drug: Clobazam;   Drug: Clonazepam;   Drug: Lorazepam
Outcome Measures: Time (measured in minutes) to onset of seizure freedom;   Reduction of seizure frequency/minute;   Mental status preservation off sedating anticonvulsants as measured by the MoCA© scale;   Ambulatory function as measured by the Hauser Ambulation Index
8 Recruiting Evaluation of the Effects of Etifoxine 100 mg and Lorazepam 2 mg on Vigilance and Cognitive Functions in the Elderly
Condition: Healthy Volunteers
Interventions: Drug: etifoxine;   Drug: lorazepam;   Drug: Placebo
Outcome Measure: Reaction time (RTI) of Cambridge Neuropsychological Test Automated Batteries (CANTAB)
9 Recruiting Evaluation of the Effects of Etifoxine 100 mg and Lorazepam 2 mg on Vigilance and Cognitive Functions in Elderly
Condition: Volunteers Aged Between 65 and 75 Years Old
Interventions: Drug: etifoxine;   Drug: Lorazepam;   Drug: Placebo
Outcome Measure: Reaction time (RTI) of Cambridge Neuropsychological Test Automated Batteries (CANTAB)
10 Recruiting Characterizing and Predicting Drug Effects on Cognition
Condition: Cognitive Deficits
Interventions: Drug: Topiramate;   Drug: Lorazepam
Outcome Measures: Relationship between neurocognitive performance and study drug plasma concentration;   Neurophysiological effect of study drug on working memory
11 Recruiting Liver Fibrosis in Alpha-1 Antitrypsin Deficiency (AATD)
Conditions: Liver Fibrosis;   Alpha-1 Antitrypsin Deficiency;   AAT Deficiency;   AATD
Interventions: Device: Abdominal ultrasound;   Procedure: History and physical;   Procedure: Intravenous catheter;   Procedure: Blood draw;   Other: Liver questionnaire;   Procedure: Liver Biopsy;   Drug: Midazolam;   Drug: Fentanyl;   Drug: Lidocaine;   Drug: Acetaminophen;   Drug: Lorazepam;   Drug: Oxycodone/Acetaminophen;   Drug: Ondansetron
Outcome Measures: To estimate the prevalence and histologic spectrum of liver injury in an adult with Alpha-1 Antitrypsin deficiency and a genotype of ZZ.;   To identify environmental and host risk factors for clinically significant liver fibrosis.;   To define the diagnostic accuracy of non-invasive markers of fibrosis in AAT liver disease.;   To explore epigenetic markers for the development of liver fibrosis.;   To quantify liver fibrosis progression.
12 Recruiting Sedative Premedication: Efficacy On Patient Experience
Condition: Perioperative Anxiety
Interventions: Drug: Lorazepam;   Other: no premedication;   Drug: Placebo (microcrystalline celluloses)
Outcome Measures: the EVAN score;   the perioperative level of anxiety
13 Not yet recruiting Explanation About Sleep in Post Trauma Patients
Conditions: Post Traumatic Stress Disorder;   Sleep Deprivation
Interventions: Behavioral: Explanation encouraging sleep;   Behavioral: Explanation discouraging sleep;   Drug: Lorazepam
Outcome Measure: PTSD severity as measured by CAPS
14 Recruiting Optimization of Procedural Sedation Protocol Used for Dental Care Delivery in People With Mental Disability
Condition: Dental Care for Disabled
Interventions: Drug: Midazolam Mylan;   Drug: Lorazepam Mylan;   Drug: Valium + Akineton + Dehydrobenzperidol + Atropine sulfate
Outcome Measures: Level of cooperation of patient when receiving regular dental care;   Recording of vital parameters during regular dental care delivery;   Level of patient comfort and possible side-effects after dental treatment session
15 Recruiting A First In Human Study In Healthy People To Evaluate Safety, Toleration, Pharmacokinetics and Pharmacodynamics of Single Oral Doses Of PF-06372865
Condition: Healthy
Interventions: Drug: PF-06372865 or Placebo;   Drug: PF-06372865 or Placebo or Lorazepam
Outcome Measures: Maximum Observed Plasma Concentration (Cmax);   Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast);   Area Under the Curve From Time Zero to Extrapolated Infinite Time;   Apparent Oral Clearance (CL/F);   Apparent Volume of Distribution (Vz/F);   Plasma Decay Half-Life (t1/2);   Area Under the Curve From Time Zero to 24 hours;   Change in Saccadic Eye Movements (saccadic reaction time, saccadic peak velocity and saccadic inaccuracy);   Change in Body Sway;   Change in Smooth Pursuit;   Change in Bond and Lader VAS;   Change in Adaptive Tracking;   Change in Visual Verbal Learning Test;   Change in Pharmaco-EEG
16 Unknown  Enteral Versus Intravenous Sedation in Critically Ill High-risk ICU Patients
Conditions: Critical Illness;   Mechanical Ventilation Complication
Interventions: Procedure: Enteral Sedation (EN);   Procedure: Control group: Intravenous Sedation (IV)
Outcome Measures: Percent of efficacy, measured by observed RASS = desired RASS ± 1.;   Sedation protocol effectiveness: percentage of "protocol violation days" on the total of ICU days.;   Delirium and coma free days (respectively negative CAM-ICU and RASS > - 3 in all daily observations until 28° ICU day) (11);   Ventilation free days (12);   Nursing evaluation of sedation adequacy (communication skills, cooperation, environment tolerance) (13);   Overall ICU and hospital mortality, absolute mortality after 1 year from ICU discharge.;   Sedative drugs costs.;   Indirect inefficacy markers
17 Recruiting Dexmedetomidine (Precedex®) for Severe Alcohol Withdrawal Syndrome (AWS) and Alcohol Withdrawal Delirium (AWD)
Conditions: Alcohol Withdrawal Delirium;   Alcohol Withdrawal Associated Autonomic Hyperactivity;   Alcohol Withdrawal Hallucinosis;   Alcohol Withdrawal-Induced Delirium Tremens
Interventions: Drug: Dexmedetomidine;   Drug: Placebo
Outcome Measures: The length of ICU stay defined as the time between randomization and ICU transfer orders.;   The number of delirium-free and ventilator-free days during the first 28 days of hospitalization;   The length in days of the hospital stay;   Scores at hospital discharge on the Mini Mental Exam, Beck Depression Inventory, Beck Anxiety Inventory and PTSD checklist.;   Resource utilization costs associated with this hospitalization.;   Predefined adverse events;   average MINDS score
18 Unknown  Continuation Electroconvulsive Therapy (C-ECT) for Relapse Prevention in Major Depression
Condition: Depression
Interventions: Device: Thrymatron System IV device (CONSOLIDATION ELECTROCONVUsLIVE THERAPY) plus PHARMACOTHERAPY;   Drug: PHARMACOTHERAPY
Outcome Measures: Hamilton Depression Rating Scale 21 items (HDRS-21);   Mini-Mental State Examination (MMSE 35);   UKU - Adverse effects rating scales;   Demographical Data Memory (MEDABI-20);   Rey Figure;   Trail Making Test A;   Trail Making Test B;   Stroop Test;   Direct and inverse digits (WAIS, Weschler Adults Intelligence Sacle).;   Vocabulary WAIS (Weschler Adults Intelligence Scale);   Frequency Hospitalization Quotient;   Hospital Day Quotient (HDQ)
19 Not yet recruiting Emesis Control Study in Non-Hodgkin Lymphoma Patients Receiving R-CHOP
Condition: Lymphoma, Non-Hodgkin
Intervention: Drug: Standard anti-emetics in conjunction with R-CHOP
Outcome Measures: Complete Response, Acute Phase (Day 1), Cycle 1;   Complete Response, Delayed Phase (Days 2 to 11), Cycle 1;   Complete Response - Cycle 2 and beyond;   No Significant Nausea - Cycle 2 and beyond;   Failure of standard anti-emetic prophylaxis, Day 1 to Day 11, Cycle 1 and beyond;   Frequency of common adverse events associated with anti-emetics;   Severity of common adverse events associated with anti-emetics
20 Recruiting TELSTAR: Treatment of ELectroencephalographic STatus Epilepticus After Cardiopulmonary Resuscitation
Conditions: Cardiac Arrest;   Postanoxic Encephalopathy;   Status Epilepticus
Interventions: Drug: Anti-epileptic drugs;   Other: No anti-epileptic drugs
Outcome Measures: Neurological outcome;   Long term outcome